.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA06_MycophenolicAcid.MycophenolicAcid

Information

Mycophenolic acid is an immunosuppressive agent that inhibits inosine monophosphate dehydrogenase, thereby blocking de novo guanosine nucleotide synthesis in T and B lymphocytes. It is used for the prevention of rejection in organ transplantation, particularly in kidney, heart, and liver transplants. The drug is approved and widely used today, often as the active metabolite of the prodrug mycophenolate mofetil.

Pharmacokinetics

Pharmacokinetic parameters of mycophenolic acid after oral administration of mycophenolate mofetil (1000 mg) in healthy adult volunteers.

References

1. Rong, Y, et al., & Kiang, TKL (2019). Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. Clinical pharmacokinetics 58(11) 1483–1495. DOI:10.1007/s40262-019-00771-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31055791

2. Rexiti, K, et al., & Wei, X (2023). Population pharmacokinetics of mycophenolic acid and dose optimisation in adult Chinese kidney transplant recipients. Xenobiotica; the fate of foreign compounds in biological systems 53(10-11) 603–612. DOI:10.1080/00498254.2023.2287168 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37991412

3. Romano-Aguilar, M, et al., & Romano-Moreno, S (2020). Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Lupus 29(9) 1067–1077. DOI:10.1177/0961203320931567 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32539658

Revisions

• 06/2025 initial generated model